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Abstract
Glycosaminoglycans (GAGs) such as chondroitin are ubiquitous disaccharide
carbohydrate chains that contribute to the formation and function of proteogly-
cans at the cell membrane and in the extracellular matrix. Although GAG-mod-
ifying enzymes are required for diverse cellular functions, the role of these
proteins in human development and disease is less well understood. Here, we
describe two sisters out of seven siblings affected by congenital limb malforma-
tion and malignant lymphoproliferative disease. Using Whole-Genome Sequenc-
ing (WGS), we identified in the proband deletion of a 55 kb region within
chromosome 12q23 that encompasses part of CHST11 (encoding chondroitin-
4-sulfotransferase 1) and an embedded microRNA (MIR3922). The deletion was
homozygous in the proband but not in each of three unaffected siblings. Geno-
typing data from the 1000 Genomes Project suggest that deletions inclusive of
both CHST11 and MIR3922 are rare events. Given that CHST11 deficiency
causes severe chondrodysplasia in mice that is similar to human limb malfor-
mation, these results underscore the importance of chondroitin modification in
normal skeletal development. Our findings also potentially reveal an unexpected
role for CHST11 and/or MIR3922 as tumor suppressors whose disruption may
contribute to malignant lymphoproliferative disease.
ª 2015 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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Introduction
Glycosaminoglycans (GAGs) such as chondroitin and der-
matan are a heterogeneous group of unbranched polysac-
charides of variable length that consist of repeating
disaccharides. With the exception of hyaluronic acid,
GAGs are synthesized in the Golgi and then modified by
enzymes including sulfotransferases. Chondroitin (the
most prevalent GAG), heparin, dermatan, and keratin are
all sulfated and subsequently appended to newly synthe-
sized proteins via O- or N-linked glycosylation to form
mature proteoglycans. Proteoglycans function at the cell
membrane or as secreted components of the extracellular
matrix (Theocharis et al. 2010).
Although GAG-modifying genes such as sulfotransferas-
es are required for normal GAG and proteoglycan synthe-
sis, the role of these genes in human development and
disease is less well understood. Here, we report a previ-
ously undescribed syndrome whose cardinal features
include bilateral bony deformities of upper and lower
extremities and susceptibility to malignant lymphoprolif-
erative disease. The phenotype was present in two of seven
siblings but in neither parent, suggestive of a genetic dis-
order with an autosomal recessive mode of inheritance.
Whole-Genome Sequencing (WGS) of the proband
revealed a biallelic 55 kb deletion at chromosome 12q23
spanning part of the locus for CHST11 and including an
embedded MIR3922. Nullizygosity for the deletion was
observed in the proband and not in three unaffected living
siblings who subsequently underwent testing. When con-
sidered together with the known role for CHST11 in mur-
ine cartilage growth plate formation during development,
our findings strongly suggest that chondroitin sulfation is
required for normal development of the bony skeleton in
humans. Our findings also support the hypothesis that
CHST11 and/or MIR3922, a microRNA whose function
has not previously been described, may act as tumor sup-
pressors in the lymphocyte lineage.
Clinical history
The proband is a 46-year-old woman who initially pre-
sented to the adult genetics clinic at Brigham and
Women’s Hospital in 2005 for evaluation of a personal
and family history of congenital hand/foot malformations
and peripheral T-cell lymphoma. At 61 in. in height (10th
percentile, CDC growth curves), she is shorter than all of
her first-degree relatives except one similarly affected sis-
ter. She was born with bony abnormalities of the fingers
and toes bilaterally, for which she underwent multiple
surgical repairs in early childhood. On clinical exam, her
fingers demonstrated brachydactyly with disproportion-
ately short index fingers and either valgus or varus defor-
mity at many of the interphalangeal (IP) joints (Fig. 1A).
Similar findings were observed in the toes. X-ray images
were taken of the hands and feet, with multiple notable
findings. On the left hand, the index finger displayed a
long proximal phalanx, a fused distal phalanx and sublux-
ation of the index metacarpophalangeal (MCP) joint with
remodeling of the bony surfaces; the third digit had four
phalanges and a horizontal articulation at the base of the
proximal phalanx; the fourth and fifth fingers each had
long proximal phalanges; and the fifth finger middle pha-
lanx had a curved articulation distally (Fig. 1B). The
metacarpals appeared more normal with the exception of
a hypoplastic index metacarpal. The thumbs and wrist
bones appeared normal. Similar findings were observed in
radiographs of the right hand (Fig. 1C).
In the left foot, plain films revealed fusion across the
great toe IP joint; small middle phalanges of the second
and third toes; and only two phalanges of the fourth toe
with a well-defined lucency at the base of the proximal
phalanx of the fourth toe, thought to be a separate ossicle
(Fig. 1D). The fifth toe showed a faint lucency with scle-
rotic margins across the proximal phalanx. The metatar-
sals demonstrated no abnormalities. The right foot
displayed similar abnormalities (Fig. 1E).
The proband’s medical history was further complicated
at 44 years of age, when she developed several weeks of
fever, flu-like symptoms, and pulmonary infiltrates unre-
sponsive to antibiotics that culminated in respiratory fail-
ure and mechanical ventilation. Extensive testing for an
infectious etiology was negative and she was diagnosed
with acute respiratory distress syndrome (ARDS) of
Figure 1. (A) At present, the hands of the proband are notable for
malformed digits. (B and C) X-rays of the hands at present. See text
for detailed description. (D and E) X-rays of the feet at present. See
text for detailed description.
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uncertain etiology. Her symptoms ultimately improved
with high-dose steroids but recurred when steroids were
discontinued. Surgical lung biopsy revealed an atypical
lymphoid infiltrate consisting primarily of CD3+ T cells
but with a minor component of CD20+ B cells. Immuno-
globulin heavy chain polymerase chain reaction (PCR)
did not identify any evidence of B-cell clonality. The his-
tologic pattern of an angiocentric lymphoid infiltrate was
suggestive of lymphomatoid granulomatosis, an Epstein–
Barr virus (EBV)-associated lymphoproliferative disorder.
However, additional evidence supporting this diagnosis
including atypical lymphoid cells reactive for B-cell anti-
gens or EBV-associated mRNAs was not identified. Bone
marrow biopsy was unremarkable. The patient was
restarted on antibiotics and steroids and improved clini-
cally. Her lung biopsy was reviewed at the National Can-
cer Institute and the overall impression was that of a
reactive process, possibly an organizing pneumonia, rather
than a primary lymphoproliferative disorder such as lym-
phomatoid granulomatosis, although the latter could not
be definitively ruled out. The patient’s condition ulti-
mately went without diagnosis.
She subsequently underwent a second lung biopsy,
again revealing nodular lymphoid infiltrates of primarily
CD3+ T cells with scattered CD20+ B cells and CD68+
histiocytes. PCR for rearranged immunoglobulin heavy
chain and T-cell receptor (TCR) genes did not demon-
strate any evidence of B- or T-cell clonality, respectively.
Flow cytometry of peripheral blood lymphocytes revealed
no abnormalities. Overall, definitive diagnostic features of
a T- or B-cell lymphoma were not observed. Based on
clinical suspicion of malignancy, the patient was treated
with rituximab followed by four cycles of chemotherapy
with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP). The patient’s clinical symptoms
improved in concert with partial regression of her pulmo-
nary infiltrates. New wedge biopsies of the right middle
and upper lobes revealed a nodular, angiocentric and
bronchocentric atypical T-cell lymphoid infiltrate extend-
ing into intra-alveolar spaces. The infiltrate was composed
of medium size and large atypical lymphoid cells admixed
with small lymphocytes and histiocytes. Immunohisto-
chemical studies revealed that the majority of large atypi-
cal lymphoid cells stained positively for the T-cell markers
CD3, CD4, and CD8 (minority). CD5 expression was
absent but for a small number of cells. The infiltrating T
cells were also positive for CD43 and TIA-1 in a granular
cytoplasmic pattern. EBV LMP-1 was negative, as were
B-cell markers CD20 and CD79a and the natural killer cell
marker CD56. Additional negative markers included
CD30, CD15, CD34, MPO, and CD1a. Ki-67 stained
approximately 20–30% of cells. EBV mRNA by in situ
hybridization was also negative. On this occasion, TCR
gamma gene rearrangement studies revealed evidence of
clonality. The patient’s progressive clinical course, the
cytologically atypical T-cell infiltrate, the immunopheno-
typic aberrancy (absence of CD5), the lack of EBV mRNA,
and molecular evidence of clonality with an identical
pattern observed at two different anatomical sites (right
middle lobe, right upper lobe) were most consistent with a
diagnosis of peripheral T-cell lymphoma. She received
additional chemotherapy prior to undergoing a matched
unrelated allogeneic bone marrow transplant from a male
donor. Her clinical course has been complicated only by
grade 1 graft versus host disease and several non-life-
threatening infections. She continues to have no evidence
of disease on periodic restaging positron emission tomog-
raphy–computed tomography (PET-CT) scans.
The proband’s family history is most notable for an
older sister with similar congenital malformation of the
hands/feet who succumbed to complications of an
unnamed lymphoproliferative disorder in her early 20s. At
a height of sixty inches, the deceased sister was also shorter
than all other first-degree relatives. A review of her medical
records from the 1980s revealed that she presented at
17 years of age with abdominal pain, nausea, and vomit-
ing, subsequently found to be caused by a small bowel
obstruction complicated by perforation and pneumoperi-
toneum. She also described a several week history of skin
lesions of uncertain origin, fever, shortness of breath, and
tachypnea. Radiographic imaging of the lungs revealed dif-
fuse bilateral nodular infiltrates. Management of the small
bowel perforation ultimately included partial ileal resec-
tion, right-sided colectomy, and jejunostomy. Per report,
pathologic evaluation of the resected small bowel revealed
dense lymphocytic infiltrates. Skin biopsy similarly
revealed a lymphocytic infiltrate. Biopsy of the lung was
notable for an angiocentric lymphocytic infiltrate resem-
bling lymphomatoid granulomatosis, the same EBV-related
condition initially suspected to underlie the proband’s pul-
monary lymphoid infiltrates. A bone marrow biopsy was
reportedly normal on two occasions. No additional molec-
ular diagnostic testing was available and/or performed at
the time. She was treated with cyclophosphamide, azathio-
prine, and prednisone with resolution of both pulmonary
infiltrates and cutaneous manifestations. However, her
course was subsequently complicated by new-onset sei-
zures. Computed tomography (CT) imaging suggested
involvement of the central nervous system (CNS) with the
lymphoproliferative disorder. A brain biopsy was per-
formed and the pathology was consistent with malignant
lymphoma of the CNS, not otherwise specified. She ulti-
mately died from complications of her disease at age 22.
The proband and her deceased sister have five
unaffected living siblings (Fig. 2). No other individuals
in the extended family are reported to have congenital
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abnormalities of the hands or feet. With the exception of
the proband’s father, who was diagnosed with chronic
lymphocytic leukemia (CLL) at age 59 and died at age 64,
no other individuals have developed any lymphoprolifera-
tive disorders. The proband’s parents were both immi-
grants to the US from the same region of Ireland, so the
possibility of distant consanguinity cannot be ruled out.
The family history is most consistent with a rare mono-
genic disorder of autosomal recessive inheritance.
A search of online databases including OMIM and
PubMed did not identify any named syndrome associated
with both skeletal dysplasia and any type of lymphoprolif-
erative disorder. Therefore, no specific candidate gene
rose to a level of suspicion to warrant clinical testing. The
results of chromosome breakage analysis with diepoxybu-
tane (DEB) were normal and therefore did not support a
diagnosis of Fanconi anemia (FA). Array-based compara-
tive genomic hybridization using a custom-designed plat-
form with 180,880 probes throughout the human genome
did not reveal any clinically significant genomic gains or
losses. Therefore, we performed WGS on genetic material
obtained from the proband to identify rare homozygous
variants that could potentially explain the phenotype in
this family.
Methods
Consent
Consent to perform WGS under Clinical Laboratory
Improvement Amendments (CLIA) conditions was
obtained under protocols approved by the Institutional
Review Board (IRB) of Partners HealthCare, Inc. Explicit
permission to publish the findings contained herein was
obtained from the proband.
Skin biopsy and fibroblast culture
Due to the patient’s prior allogeneic bone marrow
transplant, which resulted in reconstitution of the entire
hematopoietic system by donor cells, we isolated and
sequenced genomic DNA from cultured skin fibroblasts
rather than from circulating (donor) hematopoietic cells
(Valencia et al. 2014). The skin biopsy was rinsed,
minced, and then cultured in P-60 dishes containing
5 mL complete minimal essential media medium with
10% fetal bovine serum (FBS), penicillin and streptomy-
cin (100 units/mL), and gentamicin (50 lg/mL). The
dishes were incubated at 37°C with 5% CO2 and exam-
ined daily for cell growth. When the cells became 90–
100% confluent in culture, genomic DNA was isolated
from fibroblasts using the Gentra Puregene Cell Kit (QIA-
GEN, Venlo, Netherlands) and subsequently used for the
WGS sequencing.
Whole-genome sequencing
WGS was performed by the Illumina Clinical Services
Laboratory (Illumina, Inc; San Diego, CA). Briefly, geno-
mic DNA was randomly fragmented and then sequenced
using 50 nt paired-end reads on an Illumina HiSeq 2000
Sequencer at an average depth of 309 coverage (Bentley
Figure 2. The pedigree demonstrates a large sibship with two affected individuals, one deceased. The table below the pedigree indicates the
genotyping results for the proband and the three siblings who underwent testing. The data include number of CHST11 deletion alleles
(homozygous null, heterozygous, or homozygous wild type) as well as results of droplet digital PCR (exon 2, intron 1), including mean and
standard deviation. STR genotyping results (for chimerism) are also indicated.
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et al. 2008). Resulting BAM files were converted to
FASTQ format and realigned to the human reference
sequence [University of California Santa Cruz (UCSC)
hg19/GRCh37 assembly] using the Burroughs-Wheeler
Alignment tool (BWA) (Li and Durbin 2009) in paired-
end mode. Duplicated reads resulting from PCR overam-
plification or optical duplication were flagged and dis-
carded by the MarkDuplicates module of Picard tools
(version 1.67). Targeted local realignment was then per-
formed near known short insertions and deletions (indels)
and by base quality recalibration using the Genome
Analysis Toolkit (GATK, version v2.1-8-g5efb575) (McK-
enna et al. 2010; DePristo et al. 2011). Single-nucleotide
variants (SNVs) and indels were identified using batch
calling with a set of unrelated individuals by using the
Unified Genotyper module in the GATK in multisample
calling mode. Suspected sequencing artifacts that were
present across the samples of several unrelated individuals
were removed. Variant quality score recalibration was
performed using the GATK to identify a set of high-confi-
dence candidate variants. The functional consequence of
each variant was predicted using Variant Effect Predictor
(Release 71) (Yourshaw et al. 2014). Variants not found
in dbSNP (Single Nucleotide Polymorphism Database)
build 135 (Sherry et al. 2001), in the 1000 Genomes Pro-
ject (1KG) and the Exome Sequencing Project (ESP,
N = 6503) data sets were considered for analysis (NIH
2012) (1000 Genomes Project FTP Server 2012). A reces-
sive inheritance scenario was most probable in this case,
so a stringent threshold of 0.1% population frequency in
ESP and 1KG was used, resulting in rare or private candi-
date variants. Homozygous and compound heterozygous
sequence variants were evaluated. Structural variants (SV)
were identified using a panel of WGS from 946 unrelated
individuals by comparing the average coverage for con-
trols and the proband’s sample over the same exons. The
resulting SV variants were genotyped across individu-
als from the 1000 Genomes Project to assess the SV’s
population frequency, and SVs with minor allele fre-
quency over 1% were filtered using GenomeSTRiP (Hand-
saker et al. 2011).
Droplet digital PCR (ddPCR) assay
The homozygous deletion of CHST11 and MIR3922 iden-
tified by WGS of DNA from the proband’s cultured fibro-
blast cells was confirmed by testing the proband’s DNA
from both her cultured fibroblasts and buccal epithelia
simultaneously by ddPCR. TaqMan assays recognizing
target genes were designed for a region on intron 1 (also
overlapping MIR3922), exon 2 of CHST11, along with ref-
erence genes RPP30 and AP3B1 (sequences and other
information can be found in Table S1). Each assay
employed forward and reverse primers and an MGB-Taq-
Man probe labeled with either FAM- or VIC- dyes cus-
tom-designed using PrimerExpress software (Life
Technologies, Waltham, MA) and synthesized by Life
Technologies. Assays were designed specifically to exclude
a MseI cutting site within the amplicon since MseI was
used to fragment DNA into smaller pieces and to avoid
copy number polymorphisms in the general population in
the Database of Genomic Variants (MacDonald et al.
2013). The detailed workflow for ddPCR has been
described previously (Hindson et al. 2011). Raw data
analysis was automatically performed by QuantaSoft soft-
ware (Bio-Rad, Hercules, CA), followed by manual nor-
malization of the raw copy number values using a
correction factor to yield a copy number of 2.0 to the
RPP30 reference gene.
Identity testing
To confirm that deletion of CHST11 and MIR3922 was
present in the constitutional genome of the proband and
not an artifact induced by culturing skin fibroblasts, we
performed genotyping of highly polymorphic short tan-
dem repeats (STRs) using genomic DNA from the pro-
band’s buccal epithelia and cultured fibroblast cells. A
multiplex PCR reaction was performed for 16 STR loci
using the commercially available AmpFlSTR Identifil-
erTM PCR Amplification kit (Applied Biosystems; Carls-
bad, CA), following the manufacturer’s instructions.
Resulting STR amplicons were separated and visualized
using an ABI Prism (Waltham, MA) Genetic Analyzer.
STR alleles were scored using GeneMarker software v1.5
(Softgenetics, State College, PA).
Results
Given the recessive mode of inheritance observed for the
phenotype in this family, we searched the proband’s WGS
data for genes harboring rare biallelic single-nucleotide
and compound heterozygous variants (Table 1). We iden-
tified compound heterozygous variants in MBD3L5 and
PRND. A homozygous missense variant in EPHA10 and a
homozygous variant in OLA1 30UTR were also identified.
While the variants in these four genes appeared to be
technically valid, there was insufficient evidence based on
known expression and/or biological function to link these
variants to the observed phenotype.
We next examined the proband’s WGS data for homo-
zygous deletions too small to be detected by array-based
comparative genomic hybridization. Three such deletions
were identified: chr12:104,948,000-105,003,000 (55 kb),
chr19:55,253,424-55,295,014 (41.5 kb), and chr19:54,801,
000-54,807,500 (6.5 kb). The first deletion included exon 2
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of the gene CHST11 as well as the embedded microRNA
MIR3922. By computational prediction, MIR3922 may
target ZNF585A (Zinc Finger Protein 585A [19q13.12]),
RNF214 (Ring Finger Protein 214 [11q23.3]), RAB10
(RAS-Related Protein RAB-10 [2p23.3]) and/or ERBB2
(erythroblastic leukemia viral oncogene homolog 2) (Mar-
agkakis et al. 2009). The two deletions of chromosome 19
included the genes KIR2DL3, KIR2DL1, and LILRA3.
The population frequency of these homozygous dele-
tions was determined using genotyping data generated by
Genome STRiP in the 1KG cohort (Fig. 3). The two dele-
tions on chromosome 19 have many individuals with
deletions in the 1KG samples (>1%), while the deletion
on chromosome 12 that includes CHST11 and MIR3922
appears to be a rare variant, with no deletions observed
in the 1KG project. The parents of the proband were born
in the same region in Ireland, suggesting that the rare
homozygous deletion could be a part of a region where
there is identity by descent (IBD). Indeed, a potential IBD
region of approximately 180 kb overlaps the entire dele-
tion, spanning chr12:104,920,000-105,100,000 (Fig. 4).
To rule out the possibility of culture artifact causing
homozygous deletion of CHST11 and MIR3922, saliva was
obtained from the proband and genomic DNA was isolated
from buccal epithelial cells. Droplet digital PCR (ddPCR)
was performed to analyze the copy number of CHST11 and
MIR3922 alleles. The average CHST11 copy number was
confirmed to be 0 in the fibroblast cells and 1.23 in buccal
epithelial cells (r = 0.01). This unexpected result suggested
the possibility of genomic heterogeneity secondary to a
mixed population of host and donor-derived cells/genomes
or due to chimerism from variable fusion of CHST11-null
host DNA with CHST11-diploid donor genomic DNA
(Ferrand et al. 2010). To evaluate for genomic heterogene-
ity, we performed identity testing by microsatellite geno-
typing and compared the results from genomic material
isolated from fibroblasts to those from buccal epithelium
(Table S2). Analysis of microsatellite markers in genomic
Table 1. Other variants identified during whole-genome sequencing.
Gene Chromosome Coordinate Ref Alt Protein Chg Notes
Compound heterozygous variants
MBD3L5 chr19 7032665 A G R129R Synonymous
MBD3L5 chr19 7032688 T G I137S Missense
PRND chr20 4706780 C T UTR 30 Possible artifact
PRND chr20 4706782 A T UTR 30 Possible artifact
SIRT6 chr19 4174745 C A A241S Missense
SIRT6 chr19 4174758 G C N236K Missense
Homozygous alternate variants
EPHA10 chr1 38218738 G C C389W Missense
OLA1 chr2 175113308 G A UTR 30 UTR 30
Other compound heterozygous and homozygous alternative variants were identified during whole-genome sequence interpretation. These variants
have been ruled out as causal in this case using our interpretation pipeline.
Figure 3. Three homozygous deletions were identified in genomic DNA from the proband. The population frequency of these deletions was
determined using genotyping data generated by Genome STRiP in the 1000 genomes cohort. As shown in the histograms, the two deletions on
chromosome 19 have many individuals with deletions in the 1KG samples (>1%), while the deletion on chromosome 12 that includes CHST11
and MIR3922 appears to be a rare variant, with no deletions observed in the 1KG project.
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DNA isolated from fibroblast culture was consistent with
origin from a single individual. The same analysis of geno-
mic DNA isolated from buccal epithelium, however, dem-
onstrated evidence of chimerism at 13/16 loci and the
presence of a Y chromosome marker within the female pro-
band, confirming the presence of genetic material originat-
ing from the male bone marrow donor. When chimerism
was calculated on 10 of 13 informative loci the mean value
was found to be 62%, consistent with 1.23 alleles contrib-
uted by the CHST11-diploid donor as determined by
ddPCR. When taken together, these findings strongly sug-
gest that homozygous deletion of CHST11 and MIR3922 in
skin-derived fibroblasts is representative of the proband’s
germline and not the result of a culture artifact.
To determine whether deletion of CHST11 and/or
MIR3922 is likely to underlie the combined phenotype of
skeletal malformation and T-cell lymphoma in this family,
we attempted to obtain biological material from the pro-
band’s affected (deceased) sister but were ultimately
unsuccessful. Instead, we analyzed the copy number of
CHST11 and MIR3922 in the proband’s unaffected sib-
lings. A ddPCR analysis performed for the CHST11 and
MIR3922 loci did not reveal homozygous deletion of
CHST11 and MIR3922 in any of the three unaffected sib-
lings who were tested (Fig. 2).
To determine whether somatic copy number changes or
mutations in CHST11 and/or MIR3922 are commonly
found in sporadic hematologic malignancies, we searched
the Broad TumorPortal and Catalog of Somatic Mutations
in Cancer (COSMIC) databases (Koboldt et al. 2012). No
copy number variants in CHST11 (and by extension
MIR3922) were reported for the available sequences from
hematopoietic or lymphoid tumor samples. However,
somatic copy number variants in CHST11 were identified
in several solid tumor samples. In the COSMIC database
(accessed December 2013), 511 samples representing 8 of
27 solid tumor types were found to harbor copy number
loss in the CHST11 locus. CHST11 copy number loss was
most common in ovarian cancer (31.2% of samples). In
addition, 28 and 33 nonsynonymous SNVs in CHST11 are
reported in the Broad TumorPortal and COSMIC, respec-
tively. Notable variants include missense substitutions in
diffuse large B-cell lymphoma (p.P99Q) and CLL (p.R42L),
a frameshift (p.F31 fs) in clear cell renal carcinoma, and
nonsense variants in esophageal cancer (p.Q329*), lung
adenocarcinoma (p.E325*), and liver cancer (p.E239*).
The functional significance of these variants is presently
unknown. No variant data are reported for MIR3922. Of
note, a somatic translocation involving CHST11 (t(12;14)
(q23;q32)) was previously identified in a patient with B-cell
chronic lymphocytic leukemia (B-CLL) (Schmidt et al.
2004).
Discussion
In this study, we identified biallelic deletion of CHST11/
MIR3922 in the proband as the putative cause of an
unnamed autosomal recessive syndrome presenting with
congenital malformations of the digits of the upper and
lower limbs and malignant lymphoproliferative disease.
Homozygosity for the deletion allele was not observed in
three unaffected living siblings who were available for test-
ing. Unfortunately, biological material from the deceased
affected sister was not available. Although the proband’s
clonal lymphoproliferative disorder was immunophenotyp-
ically classified as T-cell lymphoma, the lack of molecular
classification of her affected sister’s lymphoma in the 1980s
prevents us from definitively associating CHST11/MIR3922
deletion specifically with abnormalities of the T-cell lineage.
The rare homozygous deletion identified in the pro-
band is unlikely to be an artifact. While ddPCR of buccal
epithelium from saliva demonstrated hemizygosity for the
CHST11/MIR3922 locus, extensive chimerism at 13 of 16
informative STR markers (including a donor Y chromo-
some) was detected in saliva from our female proband.
This suggests the contribution of donor cell-derived
Figure 4. There are very few observed sequence reads in the region between chr12:104,948,000-105,005,000, providing much more precise
resolution on the boundaries of the deletion.
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genomic DNA to the proband’s gastrointestinal tract epi-
thelium, as has been previously described (Ferrand et al.
2010; Rennert et al. 2013).
Our analysis of existing genomic databases suggests that
the CHST11 locus is relatively intolerant of deletions and
loss-of-function variants. Although a study using genome-
wide BAC aCGH relative expression levels across 95 sam-
ples reported a hemizygous deletion near the beginning of
the CHST11 gene with 4% frequency (Wong et al. 2006),
no deletion events at this locus were observed using
higher quality whole-genome sequence data across 946
samples in the 1KG data set. The same study also
reported a complex structural rearrangement encompass-
ing CHST11 and MIR3922, but similar rearrangements
were neither observed in the 1KG data set nor would nec-
essarily preclude wild-type expression and function. It
seems implausible to observe 5 true SVs in 95 samples
but no such events in 946 samples analyzed using higher
quality data and more sensitive methods of detec-
tion. Therefore, we believe that CHST11/MIR3922 SVs
are rare. In more than 63,000 exomes cataloged at
the Broad Institute, no homozygous loss-of-function vari-
ants were observed in either CHST11 or MIR3922, fur-
ther supporting the hypothesis that biallelic deletion of
the locus best accounts for the proband’s phenotype
(exome data available at http://exac.broadinstitute.org/
gene/ENSG00000171310).
Our review of the literature suggests that the combined
phenotype of skeletal dysplasia and malignant lymphopro-
liferative disease is rare. A single case report describes an
infant with short-limbed skeletal dysplasia and severe
combined immunodeficiency who developed EBV-associ-
ated B-cell lymphoma at 10 months of age (van den Berg
et al. 1997). Another report describes two sisters with
skeletal dysplasia and Hodgkin’s lymphoma arising in late
adolescence (Gokhale et al. 1995). However, no specific
genetic etiology was identified to account for the clinical
presentation.
Notably, the phenotype observed in our proband
resembles other rare Mendelian disorders that combine
skeletal anomalies with specific hematopoietic derange-
ments. The recessive disorder thrombocytopenia-absent
radius (TAR) syndrome is characterized by low platelets
and anomalies of the radius and may also present with
eosinophilia, anemia, various other skeletal abnormalities,
and disturbances of other systems (skin, cardiovascular,
neurologic). TAR has been associated with genetic vari-
ants in the gene RBM8A, a protein that serves as one
component of the multiprotein exon junction complex
bound to mRNA at splice junctions. Fanconi anemia is a
genetically heterogeneous recessive disorder that presents
with pancytopenia (or isolated cytopenias) and skeletal
anomalies such as radial aplasia and thumb aplasia or
hypoplasia, in addition to disturbances of several addi-
tional systems (genitourinary, skin, cardiac, neurologic).
The common molecular defect shared by all FA comple-
mentation groups is in DNA repair, resulting in hypersen-
sitivity to DNA cross-linking agents.
Chondroitin sulfate is the most common proteoglycan
in cartilage and is present on the surface of cells in many
tissue types as well as in the extracellular matrix. Chon-
droitin is an unbranched GAG that consists of alternating
sugars of glucuronic acid and N-acetylgalactosamine (Gal-
NAc). Sulfate moieties added at position 4 or 6 of Gal-
NAc residues alter the physiochemical properties of
chondroitin and chondroitin glycoconjugates. The
CHST11 gene encodes a chondroitin 4-sulfotransferase
localized in the Golgi apparatus that catalyzes the transfer
of sulfate to position 4 of GalNAc in chondroitin.
CHST11 is one of several known carbohydrate sul-
fotransferases, sharing four regions of homology including
50 and 30 phosphosulfate binding sites and two C-terminal
alpha helical domains. The gene CHST3, for example,
encodes a chondroitin 6-sulfotransferase that catalyzes the
transfer of sulfate to position 6 of GalNAc in chondroitin.
The association of germline variation in CHST11 with
a clinical phenotype underscores the importance of carbo-
hydrate sulfotransferase function in human biology. Biall-
elic loss-of-function mutations in genes encoding other
carbohydrate sulfotransferases have been previously
described in rare syndromes with autosomal recessive
inheritance. Homozygous or compound heterozygous
mutations in CHST3, encoding a chondroitin 6-sulfo-
transferase, are associated with recessive spondyloepiphy-
seal dysplasia and congenital joint dislocations (OMIM
143095) (Thiele et al. 2004; Unger et al. 2010). Inactivat-
ing mutations and deletions of CHST6, encoding a kera-
tan 6-sulfotransferase expressed in the human cornea,
have been associated with macular corneal dystrophy
types I and II (Akama et al. 2000; Aldave et al. 2004).
Loss-of-function mutations in CHST14, a dermatan 4-sul-
fotransferase, have been associated with Ehlers-Danlos
syndrome musculocontractural type 1 (OMIM 601776)
(D€undar et al. 2009).
The digital malformations exhibited by our proband
and reportedly present in her affected sister suggest an
important role for CHST11 in normal bone development.
Differentiation of chondrocytes is responsible for develop-
ment of a cartilage model of future bone, and chondro-
dysplasias in mice are known to be associated with bone
and joint abnormalities (McLean and Olsen 2001). In
mice, CHST11 is expressed in the apical ectodermal ridge
of developing limbs and subsequently in the cartilage
growth plate during embryogenesis (Kl€uppel et al. 2002).
Mice homozygous for a loss-of-function mutation in the
murine CHST11 homolog die within hours of birth and
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exhibit severe chondrodysplasia characterized by disorga-
nized cartilage growth plates (Kl€uppel et al. 2005). This
phenotype is associated with imbalance of chondroitin
sulfation, mislocalization of chondroitin sulfate in growth
plates, upregulation of TGF-beta and downregulation of
BMP signaling. These perturbations disturb growth plate
morphogenesis and ultimately lead to the abnormal devel-
opment of bones formed by endochondral ossification,
resulting in abnormal development of the feet after E15
and small stature. This appears consistent with the
observed human skeletal phenotype, however, as the sis-
ters were adults, there are no data available to demon-
strate whether the human developmental mechanism is
the same.
A possible functional role for CHST11 in lymphocyte
development and/or differentiation is less well under-
stood. In adult human tissues, CHST11 expression is
enriched in hematopoietic cells including peripheral leu-
kocytes, the thymus, lymph nodes, and the spleen (BioG-
PS; Hiraoka et al. 2000). During the late stages of murine
embryogenesis (E15), CHST11 is expressed in a punctate
fashion in the liver, suggestive of expression in embryonic
hematopoietic cells (Kl€uppel et al. 2002). Notably, the
CHST11/ mouse model was not reported to develop
abnormalities of lymphoid tissue or lymphocyte prolifera-
tion or differentiation. However, the early death of
CHST11/ mice may have precluded the later develop-
ment of a lymphoproliferative disorder. Alternatively, a
phenotype was present in some form but was not evalu-
ated, given the lack of any prior evidence suggesting a
functional role for CHST11 in lymphocytes. Finally, there
may be true differences between the function of CHST11
in humans and mice.
Nonetheless, prior experimental evidence implicates a
role for proteoglycan sulfation in lymphocyte differentia-
tion, supporting a plausible contribution of CHST11 defi-
ciency to malignant lymphoproliferative disease. The
enzymes required for biosynthesis of chondroitin sulfate
and heparin sulfate appear to be developmentally regu-
lated in B-cell progenitors, resting B cells, and activated B
cells (Duchez et al. 2011). Overexpression of the biosyn-
thetic enzyme for heparin sulfate in the B-cell lineage of
transgenic mice, which diminished the chondroitin sul-
fate/heparin sulfate ratio, resulted in a partial differentia-
tion block at the pro-B- to pre-B-cell transition (Duchez
et al. 2011). In a two-step culture system, chondroitin
sulfate B (CS B) was found to promote IL-4/5 driven
murine B-cell differentiation in a dose-dependent fashion,
as assayed by IgM production, the number of IgM-secret-
ing cells, and the number of CD138-positive cells (Yoshi-
hara et al. 2007). While similar studies investigating T
lymphocyte differentiation do not appear to have been
performed, the findings for B lymphocytes support a
probable role for chondroitin sulfate in normal lympho-
cyte differentiation. Notably, chondroitin sulfate was also
found to be the major secreted GAG in three leukemic
cell lines (Jurkat, a T-cell leukemia model; Daudi, a Bur-
kitt’s or B-cell leukemia model; and THP-1, an acute
monocytic leukemia cell line) and the major GAG
retained at the membrane in two of the cell lines (Jurkat,
Daudi) as assessed by chromatography (Makatsori et al.
2001). Whether chondroitin is abnormally sulfated in
these cells is presently unclear.
In addition to impaired differentiation, another hall-
mark of the transformed phenotype is dysregulated prolif-
eration. Emerging evidence suggests that CHST11 may
regulate cellular proliferation downstream of RAS/MAPK
signaling, a pathway dysregulated in both congenital syn-
dromes with risk of malignancy and many sporadic can-
cers (Rauen 2013). In fibroblasts isolated from a patient
with Costello syndrome, a disorder caused by germline
activating mutations in HRAS, CHST11 mRNA, and pro-
tein expression and chondroitin-4-sulfate were all found
to be markedly reduced (Kl€uppel et al. 2012). Moreover,
misexpression of oncogenic HRAS in normal fibroblasts
repressed CHST11 expression, indicating that CHST11 is a
negatively regulated target gene downstream of HRAS sig-
naling. Furthermore, overexpression of wild-type CHST11
in the HRAS-mutant fibroblasts rescued the excessive pro-
liferation associated with HRAS gain of function, demon-
strating that restoration of CHST11 is sufficient to reverse
an important cellular phenotype associated with malig-
nancy. It is unknown at the present time whether somatic
activating MAPK pathway mutations commonly identified
in a range of sporadic malignancies also downregulate
CHST11, and whether a change in expression of the latter
contributes to the malignant phenotype.
Based on these data, we propose the hypothesis that
loss of normal chondroitin sulfation may predispose
affected individuals to a clonal lymphoproliferative disor-
der. It is unclear whether manifestation of the phenotype
requires the contribution of other germline variants, envi-
ronmental factors, or somatic genetic mutations in the
lymphocyte lineage. It is tempting to speculate that loss
of MIR3922, the microRNA that lies within the CHST11
locus at 12q23 and is nullizygous in our proband, con-
tributes to the lymphoproliferative phenotype. Unfortu-
nately, no functional data are available at the present time
for this microRNA.
In summary, we have identified CHST11/MIR3922 dele-
tion as the presumptive cause of the complex phenotype
observed in our proband. While CHST11 deletion alone
could account for the patient’s bony malformations, the
contribution of the deletion to her T-cell lymphoprolifer-
ative disorder is less clear. Concomitant loss of MIR3922
and perhaps additional events (genetic or environmental)
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may be required for full expression of the combined phe-
notype, or it is possible that the genetic etiology of the
lymphoproliferative disorder in each sister is distinct.
Future studies could aim to directly test whether CHST11
expression is functionally required for the normal differ-
entiation and/or proliferation of T lymphocytes, using cell
lines or other in vitro models of lymphocyte differentia-
tion. Moreover, it would be useful to assess the expression
and function of MIR3922 in lymphocytes, both alone and
in combination with reduced expression of CHST11. By
analyzing mRNA and protein levels, it would also be of
interest to assess whether CHST11 expression is reduced
in sporadic hematologic malignancies, particularly because
somatic dysregulation at the genetic level was not com-
monly observed in the Broad TumorPortal or the COS-
MIC database. Finally, additional evidence linking
CHST11/MIR3922 deletion to our proband’s phenotype
may be derived from ascertainment and genetic testing of
additional families sharing a similar phenotype.
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